Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology SocietyAlexander R. Lyon, Daniel J. Lenihan, Teresa López‐Fernández et al.|European Journal of Heart Failure|2020Cited by 767
Role of Cardiovascular Imaging in Cancer Patients Receiving Cardiotoxic Therapies: A Position Statement on Behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)Jelena Čelutkienė, Alexander R Lyon, Radek Pudil et al.|European Journal of Heart Failure|2020Cited by 364
Role of Serum Biomarkers in Cancer Patients Receiving Cardiotoxic Cancer Therapies: A Position Statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of CardiologyRadek Pudil, Alexander R Lyon, Christian Mueller et al.|European Journal of Heart Failure|2020Cited by 344
Patient Phenotype Profiling in Heart Failure with Preserved Ejection Fraction to Guide Therapeutic Decision Making. A Scientific Statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of HypertensionStefan D. Anker, Giuseppe Rosano, Muhammad Usman et al.|European Journal of Heart Failure|2023Cited by 187
Cancer Diagnosis in Patients with Heart Failure: Epidemiology, Clinical Implications and Gaps in KnowledgePietro Ameri, Carlo G. Tocchetti, Marco Canepa et al.|European Journal of Heart Failure|2018Cited by 183